[Unwanted bone changes in systemic treatment with synthetic retinoids].
An update is presented of bone changes taking place in association with oral treatment with the two most relevant synthetic retinoids, 13-cis-retinoic acid (isotretinoin; Roaccutan, Accutane) and etretinate (aromatic retinoid; Tigason, Tegison). All of the important clinical studies are reviewed, including our own results concerning etretinate-associated bone changes. While there are no more doubts about the potential bone toxicity of 13-cis-retinoic acid, the possibility of etretinate-induced bone changes probably occurring within a longer latency period cannot be conclusively assessed at present. The available clinical data concerning the potential skeletal toxicity of 13-cis-retinoic acid and etretinate should be carefully taken into consideration when determining the risk/benefit ratio, especially for long-term oral retinoid treatment.
Melnik
B
B
Plewig
G
G
D000284:Administration, Oral; D001847:Bone Diseases / Q000139:chemically induced*; D001842:Bone and Bones / Q000187:drug effects*; D003872:Dermatitis / Q000188:drug therapy*; D005050:Etretinate / Q000009:adverse effects; D006801:Humans; D015474:Isotretinoin; D012176:Retinoids / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk; D014212:Tretinoin / Q000009:adverse effects
D012176:Retinoids; D014212:Tretinoin; D005050:Etretinate; D015474:Isotretinoin
Unerwünschte Knochenveränderungen unter systemischer Behandlung mit synthetischen Retinoiden.